JP2017502003A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502003A5
JP2017502003A5 JP2016538037A JP2016538037A JP2017502003A5 JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5 JP 2016538037 A JP2016538037 A JP 2016538037A JP 2016538037 A JP2016538037 A JP 2016538037A JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5
Authority
JP
Japan
Prior art keywords
phe
pro
tyr
aib
nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077240 external-priority patent/WO2015086686A2/en
Publication of JP2017502003A publication Critical patent/JP2017502003A/ja
Publication of JP2017502003A5 publication Critical patent/JP2017502003A5/ja
Pending legal-status Critical Current

Links

JP2016538037A 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド Pending JP2017502003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915662P 2013-12-13 2013-12-13
US61/915,662 2013-12-13
PCT/EP2014/077240 WO2015086686A2 (en) 2013-12-13 2014-12-10 Protease resistant peptides

Publications (2)

Publication Number Publication Date
JP2017502003A JP2017502003A (ja) 2017-01-19
JP2017502003A5 true JP2017502003A5 (enExample) 2017-12-28

Family

ID=52021207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538037A Pending JP2017502003A (ja) 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド

Country Status (11)

Country Link
US (1) US20160318987A1 (enExample)
EP (2) EP3080153A2 (enExample)
JP (1) JP2017502003A (enExample)
KR (1) KR20160098406A (enExample)
CN (1) CN105849123A (enExample)
AU (1) AU2014363547A1 (enExample)
BR (1) BR112016013157A2 (enExample)
CA (1) CA2933405A1 (enExample)
MX (1) MX2016007407A (enExample)
SG (1) SG10201805039UA (enExample)
WO (1) WO2015086686A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2017075505A2 (en) * 2015-10-28 2017-05-04 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
JP2019525732A (ja) 2016-06-09 2019-09-12 メドイミューン・リミテッドMedImmune Limited プロテアーゼ耐性一脂質付加ペプチド
CA3073806A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
DK3774862T3 (da) 2018-04-05 2022-09-05 Sun Pharmaceutical Ind Ltd Nye GLP-1-analoger
AU2021250319A1 (en) * 2020-03-31 2022-12-01 Antaros Medical Ab Selective GIP receptor agonists comprising a chelating moiety for imaging and therapy purposes
KR20230120134A (ko) * 2020-12-16 2023-08-16 메디뮨 리미티드 폴리펩티드 및 이의 용도
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1495198A (zh) * 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
WO2007090496A1 (en) * 2006-02-08 2007-08-16 Lonza Ag Synthesis of glucagon-like peptide
WO2007139589A1 (en) * 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
WO2009125424A2 (en) * 2007-12-11 2009-10-15 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
ATE487732T1 (de) * 2008-04-18 2010-11-15 Hoffmann La Roche Alpha-n-methylierung von aminosäuren
US20120264685A1 (en) * 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
US20130143800A1 (en) * 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
WO2014088631A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same

Similar Documents

Publication Publication Date Title
JP2017502003A5 (enExample)
AR096162A1 (es) Péptidos terapéuticos
TWI455721B (zh) 癌疫苗組合物
NZ600732A (en) Oxyntomodulin peptide analogue
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
JP2008510453A5 (enExample)
RU2021134101A (ru) Модифицированная j-цепь
MX2019001925A (es) Proteina de fusion del factor viii de la coagulacion sanguinea humana altamente glicosilada y metodo de fabricacion y aplicacion del mismo.
NZ600731A (en) Oxyntomodulin peptide analogue
PH12013500050A1 (en) Anticancer fusion protein
TW201613958A (en) MIC-1 fusion proteins and uses thereof
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2017522362A5 (enExample)
NZ708990A (en) Method for activating helper t cell
JP2015516983A5 (enExample)
MX2024006356A (es) Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
MX2014008028A (es) Proteina de fusion anticancerigena.
JP2019525753A5 (enExample)
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof